End to End Clinical Trial Execution with Successful Market Authorization for a Global Biopharma in Metabolic Disorders

End to End Clinical Trial Execution with Successful Market Authorization for a Global Biopharma in Metabolic Disorders

A Strategic Clinical Partnership that Delivered Ahead of Schedule

A leading global biopharmaceutical company, headquartered in India, set out to launch a pivotal Phase III trial for a chronic metabolic disorder therapy. The goal? Secure first-mover advantage in a competitive therapeutic space. But with regulatory complexities, tight timelines, and operational bottlenecks, the stakes were high.

Navitas Life Sciences supported as a trusted, agile partner by delivering clinical, regulatory, and data management solutions with speed and precision.

Key Challenges

Managing India’s evolving regulatory environment while meeting global compliance needs
Accelerating trial initiation amidst investigator onboarding and site activation delays
Finding a single partner for protocol design, full-service operations, and clinical data reporting

Impact Delivered

40% Faster Site Activation using our pre-qualified endocrinology site network
Under 8 Weeks for Ethics Approval through strategic regulatory foresight
20+ Sites Activated in 4 Weeks via streamlined contract and training workflows
On-Time Phase III Milestones met, ensuring expedited marketing approval in India
Preferred Partner Status Awarded for future global clinical programs

Get the Full Story

Complete the form and download the case study to learn how Navitas Life Sciences accelerated trial success for a chronic metabolic disorder drug and helped secure rapid market authorization.